Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ERA 25: Switching from sMRAs to Finerenone
Author(s): Beatriz Fernandez Fernandez Added: 11 months ago
ERA 2025 - Real-world outcomes show switching from treatment with steroidal mineralocorticoid receptor antagonists (sMRAs) to finerenone is a safe option in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).Dr Beatriz Fernandez Fernandez (Hospital Universitario Fundación Jiménez Dïaz, Madrid, ES) joins us to discuss real-world outcomes from a study investigating the effect of… View more

Cardiovascular Kidney Metabolic
Marina Vivarelli
Research Area(s) / Expertise:

Chronic Kidney Disease

 Job title: Laboratory of Nephrology, Bambino Gesù Children's Hospital, Rome, Italy
Dr. Marina Vivarelli is a renowned pediatric nephrologist with extensive expertise in immune-mediated renal diseases. Initially trained as a pediatrician, she developed a strong focus on pediatric immunology, working in the labs of leading experts like Fabrizio De Benedetti in Pavia and Raif Geha at Children's Hospital Boston. Since 2006, Dr. Vivarelli has been part of the Division of Nephrology… View more
HFA 24: FINE-HEART: Design & Baseline Characteristics
Author(s): Muthiah Vaduganathan Added: 2 years ago
HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the design and baseline characteristics of the FINE-HEART(Bayer) integrated pooled analysis of finerenone, an on-steroidal mineralocorticoid receptor (MRA) antagonist, in over 19000 patients with heart failure and CKD.FINE-HEART includes patients with type 2 diabetes, chronic kidney disease and/or… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Adapting the 2025 ESC Myocarditis and Pericarditis Guidelines for Asia
Author(s): Son Tran Thanh Bui , Fang Yi Lim , Louis Teo Loon Yee Added: 3 months ago

Guidelines & Statements

Pericardium Disorders
Finerenone Approved in EU for HF with LVEF ≥40%
Added: 3 weeks ago Source:  Heart Failure Academy
The European Commission has approved the non-steroidal mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia) for the treatment of adults with symptomatic chronic heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40%.¹ The approval is based on positive results from the Phase III Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients… View more

Heart Failure
Decoding the Future of HF — Key Takeaways from 2024
Author(s): Muthiah Vaduganathan , Orly Vardeny , Added: 1 year ago
Recorded at American Heart Association 2024 in Chicago, Dr Muthiah Vaduganathan (Brigham and Women’s Hospital and Harvard Medical School, Boston, US), Dr Orly Vardeny (University of Minnesota Medical School, Minneapolis, US) and Prof Pardeep Jhund (University of Glasgow, Glasgow, UK) explore cardiometabolic disease in heart failure with mid-range or preserved ejection fraction (HFmrEF and HFpEF)… View more

Heart Failure
February’s Top 10 Cardiology Resources: Videos and Essential Reads
Added: 2 months ago Source:  Radcliffe Cardiology
Explore free-to-access cardiology content, including expert video discussions, guideline-relevant analysis and peer-reviewed reviews designed for application in cardiovascular practice.New Horizons in Dyslipidaemia 2026On-Demand Video EventWith forthcoming updates anticipated at American College of Cardiology Annual Scientific Session, dyslipidaemia management is entering a period of refinement,… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Lipoprotein(a) May be Falsely Lowered When Troponin T is Elevated
Author(s): Colin Yeo , Xuan Han Koh , Weien Chow , et al Added: 1 year ago

MI/ACS

Prevention & Chronic Conditions
HFpEF in Patients Living with COPD
Author(s): Nadirah Abd Wahid , Aisya Natasya Musa , Sazzli Kasim , et al Added: 2 months ago

Heart Failure

Imaging & Diagnostics